NIKKEI 225
38,688.66 +452.59 (+1.18%) HANG SENG
18,454.96 -123.34 (-0.66%) CRUDE OIL
78.78 +0.30 (+0.38%) GOLD FUTURES
2,332.00 +0.80 (+0.03%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,304.55 -582.59 (-1.14%)
Relmada Therapeutics, Inc. (RLMD)
| Previous close | 3.6800 |
| Open | 3.7600 |
| Bid | 3.8300 x 100 |
| Ask | 3.9000 x 300 |
| Day's range | 3.6600 - 4.0000 |
| 52-week range | 2.3600 - 7.2230 |
| Volume | |
| Avg. volume | 178,893 |
| Market cap | 116.171M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.4300 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.88 |
PR NewswireRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 8, 2024.
Insider MonkeyRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript March 19, 2024 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88. RLMD isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and […]
- Thomson Reuters StreetEvents
Q4 2023 Relmada Therapeutics Inc Earnings Call
Q4 2023 Relmada Therapeutics Inc Earnings Call
